For 2024 publications go here.

JUNE

Prior D, Yang J, Nuño MM, Shaikh F, Frazier AL, Pashankar F. Standard-Dose Versus High-Dose Cisplatin for Intermediate/Poor-Risk Extracranial Malignant Germ Cell Tumors: Re-Analysis of Pediatric Oncology Group 9049 and Children's Cancer Group 8882 Trial Using Updated MaGIC Risk Stratification. Pediatr Blood Cancer. 2025 Jun;72(6):e31665.

Zhan H, Antony VM, Tang H, Theriot J, Liang Y, Hui P, Krishnamurti U, DiGiovanna MP. PTEN inactivating mutations are associated with hormone receptor loss during breast cancer recurrence. Breast Cancer Res Treat. 2025 Jun;211(2):441-447.

MAY

Chehayeb RJ, Odzer N, Albany RA, Ferrucci L, Sarpong D, Perez-Escamilla R, Lewis JB, Phipps AI, Meisner A, Pusztai L. Breastfeeding attributable fraction of triple negative breast cancer in the US. NPJ Breast Cancer. 2025 May 7;11(1):40. doi: 10.1038/s41523-025-00755-6. PMID: 40328734; PMCID: PMC12055980.

Han Y, Cai G. Intraoperative frozen section diagnosis of lung specimens: An updated review. Semin Diagn Pathol. 2025 May;42(3):150901.

Bidikian A, Bewersdorf JP, Kewan T, Podoltsev NA, Stahl M, Zeidan AM. Imetelstat in myeloid malignancies: current data and future directions. Expert Rev Anticancer Ther. 2025 May;25(5):517-528.

Alhajahjeh A, Stahl M, Kim TK, Kewan T, Stempel JM, Zeidan AM, Bewersdorf JP. Contemporary understanding of myeloid-derived suppressor cells in the acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) tumor microenvironment. Expert Rev Anticancer Ther. 2025 May;25(5):435-456.

Nomura M, Spitzer A, Johnson KC, Garofano L, Nehar-Belaid D, Galili Darnell N, Greenwald AC, Bussema L, Oh YT, Varn FS, D'Angelo F, Gritsch S, Anderson KJ, Migliozzi S, Gonzalez Castro LN, ChowdhFury T, Robine N, Reeves C, Park JB, Lipsa A, Hertel F, Golebiewska A, Niclou SP, Nusrat L, Kellet S, Das S, Moon HE, Paek SH, Bielle F, Laurenge A, Di Stefano AL, Mathon B, Picca A, Sanson M, Tanaka S, Saito N, Ashley DM, Keir ST, Ligon KL, Huse JT, Yung WKA, Lasorella A, Verhaak RGW, Iavarone A, Suvà ML, Tirosh I. The multilayered transcriptional architecture of glioblastoma ecosystems. Nat Genet. 2025 May 9.

Spitzer A, Johnson KC, Nomura M, Garofano L, Nehar-Belaid D, Darnell NG, Greenwald AC, Bussema L, Oh YT, Varn FS, D'Angelo F, Gritsch S, Anderson KJ, Migliozzi S, Gonzalez Castro LN, Chowdhury T, Robine N, Reeves C, Park JB, Lipsa A, Hertel F, Golebiewska A, Niclou SP, Nusrat L, Kellet S, Das S, Moon HE, Paek SH, Bielle F, Laurenge A, Di Stefano AL, Mathon B, Picca A, Sanson M, Tanaka S, Saito N, Ashley DM, Keir ST, Ligon KL, Huse JT, Yung WKA, Lasorella A, Iavarone A, Verhaak RGW, Tirosh I, Suvà ML. Deciphering the longitudinal trajectories of glioblastoma ecosystems by integrative single-cell genomics. Nat Genet. 2025 May 9.

Herbst RS, Chen L. The evolving immuno-angiogenic paradigm in NSCLC: lessons from ivonescimab. Nat Rev Clin Oncol. 2025 May 6.

Chen L. PD-L1 and the dawn of modern cancer immunotherapy. Nat Med. 2025 May 5.

Fereydooni S, Valdez C, Williams LC, Verma A, Judson B. Racial Disparities in Perioperative Outcomes for Patients With Head and Neck Cancer. Head Neck. 2025 May;47(5):1336-1344.

APRIL

Francisco Exposito, Kelli A. Connolly, Tang Tang, Michael Chiorazzi, Brian G. Hunt, Jordan J. Cardenas, Don X. Nguyen, Nikhil S. Joshi, and Katerina Politi. Preclinical Models of Solid Cancers for Testing Cancer Immunotherapies. Annual Review of Cancer Biology. April 2025.

Dai J, Rozenblit M, Li X, Shan NL, Wang Y, Mane S, Marczyk M, Pusztai L. Genomic alterations in normal breast tissues preceding breast cancer diagnosis. Breast Cancer Res. 2025 Apr 22;27(1):60.

Huang S, Westvold SJ, Soulos PR, Fan J, Winer EP, Zhan H, Lustberg MB, Lewin J, Robinson TJ, Dinan MA. Screening History, Stage at Diagnosis, and Mortality in Screen-Detected Breast Cancer. JAMA Netw Open. 2025 Apr 1;8(4):e255322.

Wang X, Rothen J, Huang S, Long JB, Soulos PR, Goldberg SB, Mamtani R, Presley CJ, Kunst N, Ma S, Wang SY, Gross CP, Dinan MA. Adoption of Broad Genomic Profiling in Patients With Cancer. JAMA Oncol. 2025 Apr 17:e250499.

Do LK, Lee HM, Ha YS, Lee CH, Kim J. Amino acids in cancer: Understanding metabolic plasticity and divergence for better therapeutic approaches. Cell Rep. 2025 Apr 22;44(4):115529.

Lerner BA, Gupta S, Burke CA, Kupfer S, Katona BW, Grady WM, Samadder JJ, Yurgelun MB, Kelly KJ, Moreno Prats M, Joseph N, Idos GE, Swanson BJ, Kieber-Emmons A, Weiss JM, Llor X. Advancing the Evaluation and Management of CDH1-Associated Gastric Cancer. J Natl Compr Canc Netw. 2025 Apr;23(4):e257006.

Abdou Y, Kantor O, Racz J, Newman L, Pierce LJ, Winer EP. Prognostic and Predictive Insights From Genomic Assays for Breast Cancer in Diverse Populations: A Review. JAMA Oncol. 2025 Apr 3. Epub ahead of print.

Bhatia A, Mehra R, Bauman J, Khan SA, Wei W, Neumeister V, Sandoval-Schaefer T, Alpaugh RK, Lango M, Rimm DL, Ridge JA, Burtness B. Phase II Trial of Chemotherapy, Cetuximab, and Erlotinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck. Head Neck. 2025 Apr 1. Epub ahead of print.

Quandt Z, Perdigoto A, Anderson MS, Herold KC. Checkpoint Inhibitor-Induced Autoimmune Diabetes: An Autoinflammatory Disease. Cold Spring Harb Perspect Med. 2025 Apr 1;15(4):a041603.

Chiarella LS, Huelsboemer L, Diatta F, Klimitz FJ, Kammien AJ, Kochen A, Boroumand S, Allam O, Kauke-Navarro M, Pomahac B. ASO Author Reflections: The Five-Item Modified Frailty Index in Breast Cancer Surgery: Past Insights, Present Evidence, and Future Directions. Ann Surg Oncol. 2025 Apr 4. Epub ahead of print.

Robbins CJ, Bates KM, Rimm DL. HER2 testing: evolution and update for a companion diagnostic assay. Nat Rev Clin Oncol. 2025 Apr 7. Epub ahead of print.

Chiang AC, Olmedo Garcia ME, Carlisle JW, Dowlati A, Reguart N, Felip E, Jost PJ, Steeghs N, Stec R, Gadgeel SM, Loong HH, Jiang W, Hamidi A, Parkes A, Paz-Ares L. Safety of tarlatamab with 6-8-h outpatient versus 48-h inpatient monitoring during cycle 1: DeLLphi-300 phase 1 substudy. ESMO Open. 2025 Apr 4;10(4):104538. Epub ahead of print.

Knoedler S, Diatta F, Klimitz FJ, Noel O, Kempa J, Obed D, Song SY, Mayer H, Kim BS, Kauke-Navarro M, Pomahac B, Butler PD. Unveiling Inequities: Racial Disparities in Risk-Reducing Mastectomy for Breast Cancer Prevention. Clin Breast Cancer. 2025 Apr;25(3):e312-e320.

MARCH

Bellizzi KM, Emrich M, Park CL, Magin ZE, Gnall K, Sanft T. Trajectories of aerobic physical activity and fruit and vegetable intake in adults with cancer: Predictors and outcomes of class membership. J Cancer Surviv. 2025 Mar 29. Epub ahead of print.

Kim SY, Park HS, Chiang AC. Small Cell Lung Cancer: A Review. JAMA. 2025 Mar 31. Epub ahead of print.

Detterbeck FC, Kaminski HJ, Blasberg JD, O'Connor KC. Does thymectomy in adults have long-term health consequences? J Thorac Cardiovasc Surg. 2025 Mar;169(3):787-795.e2.

Caturegli G, Zhu X, Palis B, Mullett TW, Resio BJ, Boffa DJ. Smoking Status of the US Cancer Population and a New Perspective From the National Cancer Database. JAMA Oncol. 2025 Mar 27:e250247.

Norman KE, Buss MK, Lee KA, Escobar A, Thomas J, Berg J, Uwumugambi N, Dodge LE, Han HJ, Pilgrim C, Yeh JC. Impact of a Criteria-Based Inpatient Palliative Oncology Consultation Model on End-of-Life Outcomes. J Pain Symptom Manage. 2025 Mar;69(3):229-235.e1.

Arun AS, Liarakos D, Mendiratta G, Kim J, Goshua G, Olson P, Stites EC. Integrating epidemiology and genomics data to estimate the prevalence of acquired cysteine drug targets in the U.S. cancer patient population. Pharmacogenomics J. 2025 Mar 5;25(1-2):5.

Ranjan K, Rajendran BK, Deen IU, Costantini A, de Rodas ML, Desai SS, Scallo F, Gianino N, Ferrone S, Schalper KA. IL-4 mediated TAP2 downregulation is a dominant and reversible mechanism of immune evasion and immunotherapy resistance in non-small cell lung cancer. Mol Cancer. 2025 Mar 17;24(1):80.

Su X. CAR-T Entering a New "Phase": Improving CAR-T Function by Harnessing Phase Separation. Cancer Res. 2025 Mar 14;85(6):1011-1012.

Fish AG, Park HS, Knight E, Knowlton CA, Madoff DC. Percutaneous Cryoablation of Non-small Cell Lung Cancer in Patients with Recurrence After Stereotactic Body Radiation Therapy. Cardiovasc Intervent Radiol. 2025 Mar 11.

Zhan H, Antony VM, Tang H, Theriot J, Liang Y, Hui P, Krishnamurti U, DiGiovanna MP. PTEN inactivating mutations are associated with hormone receptor loss during breast cancer recurrence. Breast Cancer Res Treat. 2025 Mar 10.

Pusztai L, Hoag JR, Albain KS, Barlow WE, Stemmer SM, Meisner A, Hortobagyi GN, Shak S, Rae JM, Baehner R, Sharma P, Kalinsky KM. Development and Validation of the RSClinN+ Tool to Predict Prognosis and Chemotherapy Benefit for Hormone Receptor-Positive, Node-Positive Breast Cancer. J Clin Oncol. 2025 Mar 10;43(8):919-928.

Tang K, Zhou L, Tian X, Fang SY, Vandenbulcke E, Du A, Shen J, Cao H, Zhou J, Chen K, Kim HR, Luo Z, Xin S, Lin SH, Park D, Yang L, Zhang Y, Suzuki K, Majety M, Ling X, Lam SZ, Chow RD, Ren P, Tao B, Li K, Codina A, Dai X, Shang X, Bai S, Nottoli T, Levchenko A, Booth CJ, Liu C, Fan R, Dong MB, Zhou X, Chen S. Cas12a-knock-in mice for multiplexed genome editing, disease modelling and immune-cell engineering. Nat Biomed Eng. 2025 Mar 20.

Herbst RS, John T, Grohé C, Goldman JW, Kato T, Laktionov K, Bonanno L, Tiseo M, Majem M, Dómine M, Ahn MJ, Kowalski DM, Pérol M, Sriuranpong V, Özgüroğlu M, Bhetariya P, Markovets A, Rukazenkov Y, Muldoon C, Robichaux J, Hartmaier R, Tsuboi M, Wu YL. Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer. Nat Med. 2025 Mar 17.

Kuhn TN, Engelhardt WD, Kahl VH, Alkukhun A, Gross M, Iseke S, Onofrey J, Covey A, Camacho JC, Kawaguchi Y, Hasegawa K, Odisio BC, Vauthey JN, Antoch G, Chapiro J, Madoff DC. Artificial Intelligence-Driven Patient Selection for Preoperative Portal Vein Embolization for Patients with Colorectal Cancer Liver Metastases. J Vasc Interv Radiol. 2025 Mar;36(3):477-488.

Kimchi G, Lamsam L, Gu B, Mendel E, Harel R, Knoller N, Cohen ZR, Ungar L, Zibly Z. Minimally Invasive Anterolateral Cervical Cordotomy for Intractable Cancer Pain Using Microtubular Retractors: A Single Institution Case Series. Oper Neurosurg (Hagerstown). 2025 Mar 1;28(3):386-390.

Cannataro VL, Bracci PM, Taylor JW, McCoy L, Rice T, Hansen HM, Heffernan AE, Wiemels J, Wiencke J, Wrensch M, Claus EB. Glioma mutational signatures associated with haloalkane exposure are enriched in firefighters. Cancer. 2025 Mar 15;131(6):e35732.

Norman KE, Buss MK, Lee KA, Escobar A, Thomas J, Berg J, Uwumugambi N, Dodge LE, Han HJ, Pilgrim C, Yeh JC. Impact of a Criteria-Based Inpatient Palliative Oncology Consultation Model on End-of-Life Outcomes. J Pain Symptom Manage. 2025 Mar;69(3):229-235.e1.

Clark CJ, Wang R, Wiemels JL, Metayer C, Deziel NC, Ma X. Perinatal exposure to ambient fine particle air pollution and risk of childhood ewing sarcoma in a population-based case-control study in California (1988-2015). Environ Health. 2025 Mar 7;24(1):6.

Hamid SA, Lee DH, Herrin J, Yu JB, Pollack CE, Dean LT, Gaddy JJ, Oladele CR, Feder SL, Canavan ME, Nunez-Smith M, Soulos PR, Gross CP. Mediators of Racial Inequities in Non-Small Cell Lung Cancer Care. Cancer Med. 2025 Mar;14(5):e70757.

Lopez de Rodas M, Villalba-Esparza M, Sanmamed MF, Chen L, Rimm DL, Schalper KA. Biological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach. Nat Rev Clin Oncol. 2025 Mar;22(3):163-181.

Nassar AH, Abou Alaiwi S, El Zarif T, Denu R, Macaron W, Abdel-Wahab N, Freeman D, Vasbinder A, Hayeck S, Anderson E, Goodman RS, Johnson DB, Grynberg S, Shapira R, Kwan JM, Woodford R, Long GV, Haykal T, Dent S, Kojima Y, Yonemor K, Tandon A, Trevino A, Akhter N, Yang EH, Hui G, Drakaki A, El-Am E, Kozaily E, Al-Hader A, Bou Farhat E, Babu P, Mittra A, Li M, Jones N, Baena J, Juarez Herrera M, Foderaro S, Nana FA, Kim C, Sackstein P, Parikh K, Desai AP, Smith C, Cortellini A, Pinato DJ, Korolewicz J, Lopetegui-Lia N, Funchain P, Choudhary A, Asnani A, Navani V, Meyers D, Stukalin I, Ocejo Gallegos JA, Trent J, Nusrat S, Malvar C, McKay RR, Neilan TG, Choueiri TK, Naqash AR. Safety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective study. J Immunother Cancer. 2025 Mar 3;13(3):e009364.

Belitzky E, Ravani Carvalho LV, Taylor M, Ortiz CN, Baum L, Fiellin DA, Lustberg MB. Psychedelics for Cancer Pain and Associated Psychological Distress: A Narrative Review of a Potential Strategy. Cancer Med. 2025 Mar;14(5):e70586.

Gaspar E, Yi I, Bar N. Once weekly bortezomib decreases rates of peripheral neuropathy without diminishing efficacy as compared to twice weekly bortezomib in combination with lenalidomide, dexamethasone and daratumumab, a single center retrospective analysis. Leuk Lymphoma. 2025 Mar 10:1-4.

Herbst RS, John T, Grohé C, Goldman JW, Kato T, Laktionov K, Bonanno L, Tiseo M, Majem M, Dómine M, Ahn MJ, Kowalski DM, Pérol M, Sriuranpong V, Özgüroğlu M, Bhetariya P, Markovets A, Rukazenkov Y, Muldoon C, Robichaux J, Hartmaier R, Tsuboi M, Wu YL. Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer. Nat Med. 2025 Mar 17.

FEBRUARY

Taddei, Tamar H.1,2; Brown, Daniel B.3; Yarchoan, Mark4; Mendiratta-Lala, Mishal5; Llovet, Josep M.6,7,8. Critical Update: AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology ():10.1097/HEP.0000000000001269, February 24, 2025.

Braun DA, Moranzoni G, Chea V, McGregor BA, Blass E, Tu CR, Vanasse AP, Forman C, Forman J, Afeyan AB, Schindler NR, Liu Y, Li S, Southard J, Chang SL, Hirsch MS, LeBoeuf NR, Olive O, Mehndiratta A, Greenslade H, Shetty K, Klaeger S, Sarkizova S, Pedersen CB, Mossanen M, Carulli I, Tarren A, Duke-Cohan J, Howard AA, Iorgulescu JB, Shim B, Simon JM, Signoretti S, Aster JC, Elagina L, Carr SA, Leshchiner I, Getz G, Gabriel S, Hacohen N, Olsen LR, Oliveira G, Neuberg DS, Livak KJ, Shukla SA, Fritsch EF, Wu CJ, Keskin DB, Ott PA, Choueiri TK. A neoantigen vaccine generates antitumour immunity in renal cell carcinoma. Nature. 2025 Feb 5.

Coppersmith NA, Schultz KS, Esposito AC, Cruickshank K, Saleh A, Linhares SM, Leeds IL, Pantel HJ, Reddy VB, Longo WE, Mongiu AK. Colorectal surgeon practice patterns of low anterior resection syndrome after rectal cancer treatment. Support Care Cancer. 2025 Feb 24;33(3):218.

Turan V, Bedoschi G, Lee DY, Barbosa CP, de Oliveira R, Sacinti KG, Sonmezer M, Lambertini M, Massarotti C, Schaub A, Wang E, Gayete-Lafuente S, Dunlop C, Anderson RA, Bang H, Oktay KH. Trends and Regional Differences for Fertility Preservation Procedures in Women With Breast Cancer. Clin Breast Cancer. 2025 Feb;25(2):108-116.e1.

Turocy T, Crawford JM. Bacterial small molecule metabolites implicated in gastrointestinal cancer development. Nat Rev Microbiol. 2025 Feb;23(2):106-121.

Experiences of Simulated Phone Death Notification. Murtha TD, Johnson RR, Ellman MS, Martin AS, Morrison LJ, Talwalkar JS.Clin Teach. 2025 Feb;22(1):e13846.

Prostate cancer in people with HIV. Sigel K, Yu R, Chiao E, Deshmukh A, Leapman MS. Curr Opin Infect Dis. 2025 Feb 1;38(1):10-17.

Wang M, Cai G, Gilani SM. TRPS1 expression in cytologic specimens of salivary duct carcinoma and other salivary gland tumors. Ann Diagn Pathol. 2025 Feb;74:152406.

Marczyk M, Kahn A, Silber A, Rosenblit M, Digiovanna MP, Lustberg M, Pusztai L. Trends in breast cancer-specific death by clinical stage at diagnoses between 2000 and 2017. J Natl Cancer Inst. 2025 Feb 1;117(2):287-295.

Cecchini M, Pilat MJ, Uboha N, Azad NS, Cho M, Davis EJ, Ahnert JR, Tinoco G, Shapiro GI, Khagi S, Powers B, Spencer K, Groisberg R, Drappatz J, Chen L, Das B, Bao X, Li J, Narayan A, Vu D, Patel A, Niger M, Doroshow D, Durecki D, Boerner SA, Bindra R, Ivy P, Shyr D, Shyr Y, LoRusso PM. Olaparib in treatment-refractory isocitrate dehydrogenase 1 (IDH1)- and IDH2-mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial. Cancer. 2025 Feb 15;131(4):e35755.

Robles JT, Stiegler AL, Boggon TJ, Turk BE. Cancer hotspot mutations rewire ERK2 specificity by selective exclusion of docking interactions. J Biol Chem. 2025 Feb 25:108348.

Ko CJ. Healing while healing: Navigating breast cancer as a doctor. J Am Acad Dermatol. 2025 Feb 21:S0190-9622(25)00326-3.

Cecchini M, Pilat MJ, Uboha N, Azad NS, Cho M, Davis EJ, Ahnert JR, Tinoco G, Shapiro GI, Khagi S, Powers B, Spencer K, Groisberg R, Drappatz J, Chen L, Das B, Bao X, Li J, Narayan A, Vu D, Patel A, Niger M, Doroshow D, Durecki D, Boerner SA, Bindra R, Ivy P, Shyr D, Shyr Y, LoRusso PM. Olaparib in treatment-refractory isocitrate dehydrogenase 1 (IDH1)- and IDH2-mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial. Cancer. 2025 Feb 15;131(4):e35755.

Turan V, Bedoschi G, Lee DY, Barbosa CP, de Oliveira R, Sacinti KG, Sonmezer M, Lambertini M, Massarotti C, Schaub A, Wang E, Gayete-Lafuente S, Dunlop C, Anderson RA, Bang H, Oktay KH. Trends and Regional Differences for Fertility Preservation Procedures in Women With Breast Cancer. Clin Breast Cancer. 2025 Feb;25(2):108-116.e1.

Exarchos A, Bourla AB, Kaur M, Schulze K, Maund S, Cao Y, Zhao Y, Williams EH, Gaffey SC, Zuniga R, Lakhanpal S, Antic V, Doral M, Sy J, Meropol NJ, Chiang AC. Real-world enrollment for a prospective clinico-genomic database using a pragmatic technology-enabled platform. Contemp Clin Trials Commun. 2025 Feb 4;44:101446.

JANUARY

Rodríguez YM, Koomson AA, Perry RJ. Breast cancer shares many epidemiological, lifestyle, and local hormonal and metabolic underpinnings with endometrial and ovarian cancer: a narrative review. Transl Breast Cancer Res. 2025 Jan 21;6:8.

Ayoade OF, Canavan ME, Zolfaghari EJ, Caturegli G, Kim SY, Boffa DJ. Recent Survival Gains in Stage IV NSCLC by Sociodemographic Strata. JTO Clin Res Rep. 2025 Jan 17;6(4):100798.

Butensky SD, Kerekes D, Bakkila BF, Billingsley KG, Ahuja N, Johnson CH, Khan SA. Quality of gastrointestinal surgical oncology care according to insurance status. J Gastrointest Surg. 2025 Mar;29(3):101961. Epub 2025 Jan 10.

Canavan ME, Westvold S, Csik V, Franks J, Rocque G, Gross CP, Adelson KB. The association between clinical trial participation, drug costs, and performance in the Oncology Care Model (OCM). J Natl Cancer Inst. 2025 Jan 22:djaf008.

Sundaresan VM, Smani S, Rajwa P, Renzulli J, Sprenkle PC, Kim IY, Leapman MS. Prostate-specific antigen screening for prostate cancer: Diagnostic performance, clinical thresholds, and strategies for refinement. Urol Oncol. 2025 Jan;43(1):41-48.

Kudo M, Ren Z, Guo Y, Han G, Lin H, Zheng J, Ogasawara S, Li H, Kim JH, Zhao H, Li CL, Madoff DC, Ghobrial RM, Kawaoka T, Gerolami R, Ikeda M, Kumada H, El-Khoueiry AB, Vogel A, Peng X, Mody K, Dutcus C, Dubrovsky L, Siegel AB, Finn RS, Llovet JM; LEAP investigators. Lenvatinib plus pembrolizumab plus transarterial chemoembolisation (TACE) versus dual placebo plus TACE for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a randomised, double-blind, phase 3 study. Lancet 2025 Jan 18;405(10474):203-215.

Ng M, Cerezo-Wallis D, Ng LG, Hidalgo A. Adaptations of neutrophils in cancer. Immunity. 2025 Jan 14;58(1):40-58.

Rios-Hoyo A, Xiong K, Dai J, Yau C, Marczyk M, Garcia-Milian R, Wolf DM, Huppert LA, Nanda R, Hirst GL, Cobain EF, van 't Veer LJ, Esserman LJ, Pusztai L. Hormone Receptor-Positive HER2-Negative/MammaPrint High-2 Breast Cancers Closely Resemble Triple-Negative Breast Cancers. Clin Cancer Res. 2025 Jan 17;31(2):403-413.

Ayoade OF, Canavan ME, De Santis WP, Zhan PL, Boffa DJ. Surgical and endoscopic management of clinical T1b esophageal cancer. J Thorac Cardiovasc Surg. 2025 Jan;169(1):279-288.e5.

Harrington K, Kitano S, Gambardella V, Parkes EE, Moreno I, Alonso G, Doi T, Berz D, Gutierrez ME, Fernandez N, Schmohl M, Barrueco J, LoRusso P. Open-label, phase Ia study of STING agonist BI 1703880 plus ezabenlimab for patients with advanced solid tumors. Future Oncol. 2025 Jan;21(2):195-200.

Lu BY, Lucca LE, Lewis W, Wang J, Nogueira CV, Heer S, Rayon-Estrada V, Axisa PP, Reeves SM, Buitrago-Pocasangre NC, Pham GH, Kojima ML, Wei W, Aizenbud L, Bacchiocchi A, Zhang L, Walewski JJ, Chiang V, Olino K, Clune J, Halaban R, Kluger Y, Coyle AJ, Kisielow J, Obermair FJ, Kluger HM, Hafler DA. Circulating tumor-reactive KIR+CD8+ T cells suppress anti-tumor immunity in patients with melanoma. Nat Immunol. 2025 Jan;26(1):82-91.

Khubchandani JA, Suttiratana SC, Washington R, White-Bracey D, Kc M, Silber A, Fayanju OM, Butler PD, Menon A, Greenup RA. Living Flat: Stories from Women of Color After Mastectomy. Ann Surg Oncol. 2025 Jan;32(1):104-114.

Junejo MH, Oyebanji OI, Wang B, Cappello C, Wait B, Farrow E, Nathan M, Bowring J, Cuming T. Early detection of anal squamous cell carcinoma with the use of high-resolution anoscopy. Clin Exp Dermatol. 2025 Jan 27;50(2):395-398.

Are C, Schissel M, Murthy S. Series on The Lancet Oncology Commission on Global Cancer Surgery-Action 1: Clinical Care and Access to Cancer Surgery. Ann Surg Oncol. 2025 Jan;32(1):42-46.

Rozenblit M, Qing T, Ye Y, Zhao H, Hofstatter E, Singh V, Reisenbichler E, Murray M, Pusztai L. Rare germline variants in cancer-relevant genes are associated with breast cancer risk in young women with high-risk family history. Breast Cancer Res Treat. 2025 Jan;209(1):21-26.

Wang Y, Zhang Y, Li W, Salovska B, Zhang J, Li T, Li H, Liu Y, Kaczmarek LK, Pusztai L, Klein DE. GABAA receptor π forms channels that stimulate ERK through a G-protein-dependent pathway. Mol Cell. 2025 Jan 2;85(1):166-176.e5.

Jiang Z, Bi F, Ge Z, Mansolf M, Hartwich TMP, Kolesnyk V, Yang K, Park W, Kim D, Grechukhina O, Hui P, Kim SW, Yang-Hartwich Y. SORL1-Mediated EGFR and FGFR4 Regulation Enhances Chemoresistance in Ovarian Cancer. Cancers (Basel). 2025 Jan 13;17(2):244.

AACR Cancer Progress Report 2024 Steering Committee. New Approvals Advancing Blood Cancer Medicine. Blood Cancer Discov. 2025 Jan 8;6(1):5-9.

Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer with 34+ contributing authors including DiGiovanna, M. of Yale. 15 Jan 2025 N Engl J Med 2025;392:249-257

Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced splicing factor-mutant myeloid malignancies. Bewersdorf JP, Mi X, Lu B, Kuykendall A, Sallman D, Patel M, Stevens D, Philipovskiy A, Sutamtewagul G, Masarova L, Keiffer G, Verma A, Bhagwat N, Wang M, Moore A, Rager J, Heiser D, Ro S, Hong WJ, Abdel-Wahab O, Stein EM. Leukemia. 2025 Jan 24.

Comparison of incident breast cancer cases in the largest national US tumor registries. Plichta JK, Thomas SM, Chanenchuk TC, Chan K, Hyslop T, Hwang ES, Greenup RA. Cancer. 2025 Jan 1;131(1):e35525. Online ahead of print

Prostate-specific antigen screening for prostate cancer: Diagnostic performance, clinical thresholds, and strategies for refinement. Sundaresan VM, Smani S, Rajwa P, Renzulli J, Sprenkle PC, Kim IY, Leapman MS Urol Oncol. 2025 Jan;43(1):41-48. doi: 10.1016/j.urolonc.2024.06.003.

Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline. #10; Click to follow link.">Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline. Yu EY, Rumble RB, Agarwal N, Cheng HH, Eggener SE, Bitting RL, Beltran H, Giri VN, Spratt D, Mahal B, Lu K, Crispino T, Trabulsi EJ. J Clin Oncol. 2025 Jan 9:JCO2402608.

Immunogenomic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma. Jammihal T, Saliby RM, Labaki C, Soulati H, Gallegos J, Peris A, McCurry D, Yu C, Shah V, Poduval D, El Zarif T, El Ahmar N, Laimon YN, Eid M, Sheshdeh AB, Krajewski KM, Büttner FA, Schwab M, Heng D, Casellas RC, Rai K, Zacharias Millward NM, Msaouel P, Karam J, Signoretti S, Van Allen E, Choueiri TK, Braun DA, Shukla SA. Nat Cancer. 2025 Jan 9.

DNA methylation in mammalian development and disease. Smith ZD, Hetzel S, Meissner A. Nat Rev Genet. 2025 Jan;26(1):7-30.

Varying the intensity of cystoscopic surveillance for high-risk non-muscle-invasive bladder cancer. Su ZT, Florissi IS, Mahon KM, Li T, Rezaee ME, Singla N, Patel SH, Townsend JP, Kates MR. BJU Int. 2025 Jan;135(1):148-155.

AAHPM Assessment Workgroup: Hospice and Palliative Medicine Fellowship Assessment Needs and Directions. Ketterer B, Dingfield L, Stowers KH, Morrison K, Bailey A, Flint H, Buckholz G, Morrison LJ, Yang H, Berns S. J Pain Symptom Manage. 2024 Dec 19:S0885-3924(24)01210-7.

Tumor-Specific Antigen Delivery for T-cell Therapy via a pH-Sensitive Peptide Conjugate. Yurkevicz AM, Liu Y, Katz SG, Glazer PM. Mol Cancer Ther. 2025 Jan 2;24(1):105-117.

Sorafenib or anthracycline-based chemotherapy for progressive desmoid tumors. Costa PA, Arora A, Fernandez Y, Yi I, Bakkila B, Tan H, Barreto Coelho P, Campoverde L, Hardy N, Bialick S, Espejo Freire A, D'Amato GZ, Chang YC, Mesenger JP, Subhawong T, Haims A, Hurwitz M, Olino K, Turaga K, Deshpande H, Trent J. Cancer. 2025 Jan 1;131(1):e35647.